Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Tegaserod for improvement of upper-GI symptoms in patients with functional heartburn

Tegaserod significantly improves esophageal mechanical pain threshold, regurgitation, and global preference vs. placebo in patients with functional heartburn, suggests a study in the July issue of Gastroenterology.

News image

fiogf49gjkf04

Tegaserod is a 5-HT4 receptor partial agonist that is used to effectively treat constipation-predominant irritable bowel syndrome.

It works by enhancing gastrointestinal motility and reducing visceral pain.

It is believed that through its neuromodulatory action, Tegaserod may also improve the symptoms of functional heartburn, by the same mechanisms within the esophagus.

Researchers from the Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, USA, therefore set out to determine if this was the case.

The scientists investigated whether Tegaserod given at 6 mg BID could do any of 3 things in patients with functional heartburn.

They compared Tegaserod to a placebo in these patients to see if the treatment could; raise esophageal pain threshold to mechanical and chemical stimuli, improve upper and lower GI symptom profile (occurrence, frequency, severity and distress), and increase global preference compared to the placebo.

Seventy patients who had given informed consent were screened, from which 42 evaluable patients with heartburn were obtained (15 male, 27 female, age range 20 – 68 years).

At screening the patients underwent esophageal manometry, 24-hour pH-metry, esophageal gastroduodenoscopy, esophageal balloon distention and Bernstein acid infusion.

Treatment with Tegaserod was associated with a higher rate of diarrhea
Gastroenterology

Study patients were then randomly assigned to Tegaserod 6 mg BID and placebo for 14 consecutive days, in a crossover design, separated by a 7 – 10 day washout period.

After each treatment regimen, patients underwent esophageal acid infusion and balloon distention and also completed a GI multi-symptom questionnaire, with occurrence, frequency, severity and level of distress collected for each symptom.

Following completion of the study, patients were asked to rate their preference for overall treatment regimen.

The study showed that Tegaserod significantly increased both the balloon pressure and balloon volume required to induce pain.

The mean and the maximum wall tension of the balloon at the pain threshold were also increased with Tegaserod.

Tegaserod had no effect on pain threshold to acid infusion.

However, there was a significant decrease in occurrence of heartburn/acid reflux and regurgitation, as well as a reduction in the level of distress perceived from the regurgitation, when Tegaserod was used.

Treatment with Tegaserod was associated with a higher rate of diarrhea, but despite this, no withdrawals from treatment took place as a result of this side effect.

Global treatment preference was 63.4% for tegaserod, and 12.2% for placebo. 24.4% of patients had no treatment preference.

Concluding on behalf of his fellow authors, S. Rodriguez-Stanley said, "Tegaserod significantly improved esophageal pain threshold to mechanical distention; however, tegaserod did not alter acid sensitivity."

He continued, "This supports separate chemical and mechanical pain pathways in the esophagus, " and added, "Tegaserod improved distressing upper GI symptoms in patients with functional heartburn, particularly regurgitation."

Gastroenterology 2004; 127 (1): 331
09 July 2004

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us